Analysts foresee more revenue Biogen

For this year Biogen's revenue will be around 13,74 billion USD. This is according to the average of the analysts' estimates. This is slightly more than 2017's revenue of 13,45 billion USD.

Historical revenues and results Biogen plus estimates 2018

stock analysis

The analysts expect for 2018 a net profit of 5,68 billion USD. The majority of the analysts expects for this year a profit per share of 28,91 USD. So the price/earnings-ratio equals 7,91.

Analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a low 0,5 percent.

Latest estimates around 234 USD

The latest 3 recommendations for the biotech company were provided by BMO Capital Markets, UBS and Morgan Stanley.

Biogen's market capitalization is based on the number of outstanding shares around 48,39 billion USD. The Biogen stock was the past 12 months quite unstable. Since last April the stock is 12 percent lower. This year the stock price moved between 216 and 389 dollar. Since 2008 the stock price is almost 440 percent higher.

Historical stock prices Biogen

stock analysis biogen News Wire & Equity Research: +31 084-0032-842

Copyright B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.